4 Enrollment Efficiency Metrics Every Coordinator Should Track

It is 8:30 AM on a Tuesday, and your desk is already stacked with charts. You have three monitoring visits scheduled this week, an amendment to submit to the Institutional Review Board (IRB), five patient follow-up visits, and an urgent email from the study sponsor asking why your site is behind on target recruitment for an oncology protocol.

If you are a Clinical Research Coordinator (CRC), this scenario is not the exception—it is the baseline.

Industry data underscores the reality: nearly 80% of clinical trials fail to meet their enrollment deadlines , and upwards of 55% of clinical trials terminate early due to insufficient patient accrual . Yet, the burden of these failures rarely falls on clinical design; it falls on the operational bottlenecks at the site level. Coordinators routinely spend between 15 to 25 hours per week manually mining electronic health records (EHRs), answering unvetted inquiries, and playing phone tag with disqualified leads.

Without clear productivity tracking and actionable efficiency metrics , tracking recruitment becomes a guessing game. Worse, site staff end up running on a hamster wheel of high-effort, low-yield activity.

To run faster, more predictable trials, sites and sponsors must measure the right recruitment performance indicators. Integrating intelligent automation and AI patient recruitment platforms like TheraNovex turns these metrics from vanity numbers into clinical velocity.

The Core Challenge: Activity Does Not Equal Productivity

In clinical research, effort does not automatically translate to enrolled patients. A coordinator can spend an entire eight-hour shift combing through patient lists and reach out to thirty candidates, only to discover that twenty-eight do not meet an obscure secondary exclusion criterion.

At the end of the day, that coordinator worked relentlessly, but their yield was near zero.

The traditional model of clinical recruitment relies on brute-force human labor. When enrollment falls behind, sponsors and contract research organizations (CROs) often advise sites to simply "do more outreach." But asking overworked coordinators to review more charts manually only compounds burnout and increases protocol deviation risks.

This is where precise efficiency metrics matter. By deconstructing the patient recruitment funnel into measurable stages, research coordinators and site managers can pinpoint exactly where candidates fall through the cracks. More importantly, understanding these metrics illustrates why AI-driven workflows—such as those pioneered by TheraNovex—are no longer an operational luxury, but a structural necessity.

4 Essential Enrollment Efficiency Metrics to Track

To transform your site’s operational performance , you need to track indicators that reveal true productivity. Here are the four foundational metrics every coordinator and site director should monitor, along with the strategies to optimize them.

PATIENT RECRUITMENT FUNNEL ┌─────────────────────────────────┐ │ Total Records Reviewed │ └────────────────┬────────────────┘ ▼ ┌─────────────────────────────────┐ │ Pre-Screening Eligibility │ ◄── Metric 1: Review-to-Screen Ratio └────────────────┬────────────────┘ ▼ ┌─────────────────────────────────┐ │ Initial Patient Contact │ ◄── Metric 3: Time-to-First-Contact (TTFC) └────────────────┬────────────────┘ ▼ ┌─────────────────────────────────┐ │ Informed Consent Signed │ ◄── Metric 2: Pre-Screening Conversion └────────────────┬────────────────┘ ▼ ┌─────────────────────────────────┐ │ Randomized Patients │ ◄── Metric 4: Accrual Velocity └─────────────────────────────────┘

What It Measures: The number of patient charts a coordinator must review to identify one viable candidate who qualifies for formal pre-screening.

Formula: Total Records Reviewed / Candidates Identified for Screening

The Traditional Baseline: In complex indications—such as rare diseases, targeted immuno-oncology, or neurological conditions—this ratio is frequently 50:1 or higher . A coordinator might examine 100 patient charts just to find two individuals who meet every inclusion and exclusion criterion.

Why It Matters for Coordinators: A high ratio indicates that coordinators are drowning in administrative noise. Manual EHR searches are constrained by keyword matching and disorganized unstructured notes. When site staff spend 80% of their recruitment capacity reading irrelevant progress notes, their time for patient engagement vanishes.

The TheraNovex Advantage: TheraNovex addresses this bottleneck using advanced natural language processing (NLP) and predictive clinical algorithms. Instead of leaving coordinators to read hundreds of pages of unstructured clinical text, TheraNovex scans structured EHR data, pathology reports, and physician progress notes simultaneously. It matches criteria with nuanced precision, dropping the Chart Review-to-Screen ratio closer to 5:1 . Coordinators receive a pre-filtered list of clinically matched candidates, restoring hours of productive time to their workweek.

2. Pre-Screening Conversion Rate (Screen-to-Consent Rate)

What It Measures: The percentage of identified prospective patients who pass initial screening criteria, attend the consent visit, and sign the Informed Consent Form (ICF).

Formula: (Consented Patients / Pre-Screened Candidates) x 100

The Traditional Baseline: Across most therapeutic areas, standard pre-screening conversion rates hover between 7% and 12% . A huge volume of candidates drop out because their initial screening was superficial—relying on demographic filters that missed subtle protocol conflicts like concomitant medications or previous therapy lines.

Why It Matters for Coordinators: Every disqualified candidate scheduled for an in-person screening consumes coordinator time, clinic space, and investigator resources. Bringing an unqualified patient into the clinic is one of the costliest disruptions a site can experience.

The TheraNovex Advantage: By analyzing deep multimodal data sets before a patient is ever contacted, TheraNovex’s AI recruitment algorithms pre-qualify candidates against granular protocol requirements. The system screens for subtle exclusion factors—such as specific laboratory cutoff values, washout periods, and comorbidities—before recommending outreach. Sites using TheraNovex typically see pre-screening conversion rates climb to 25% to 35% , minimizing wasted clinic visits and coordinator frustration.

What It Measures: The elapsed time between a prospective patient expressing interest (or an automated trigger flagging a viable candidate) and the coordinator’s first outreach call or message.

Formula: Timestamp of Outreach - Timestamp of Identification

The Traditional Baseline: At busy research sites, the average TTFC ranges from 4 to 7 business days . Inquiries sit in web portals, Voicemail boxes fill up, and unread patient referrals languish in shared inbox folders.

Why It Matters for Coordinators: Consumer behavior applies to clinical research: patient motivation drops significantly over time. Research shows that contacting a candidate within 24 to 48 hours increases the likelihood of booking a screening visit by more than 300% . When coordinators take days to follow up, patients often reconsider, experience communication anxiety, or choose alternative care paths.

The TheraNovex Advantage: TheraNovex eliminates referral stagnation through automated lead routing and intelligent communication sequencing. The platform immediately notifies coordinators when a pre-qualified candidate matches a trial, tracks outreach cadences, and can initiate automated, compliant pre-engagement messaging. This workflow shortens TTFC from days down to hours, keeping patient motivation high while taking manual tracking spreadsheets off the coordinator’s desk.

4. Accrual Velocity (Patients Randomized Per Site Per Month)

What It Measures: The actual rate at which patients clear screening, meet all baseline criteria, and are actively randomized into the study over a given time interval.

Formula: Total Randomized Patients / Number of Active Study Months

The Traditional Baseline: According to clinical benchmark studies, the average site across all therapeutic areas randomizes between 0.2 and 0.6 patients per month . Many sites end up as "zero-enrolling" or "one-and-done" contributors, adding substantial monitoring overhead for sponsors without generating meaningful data.

Why It Matters for Coordinators: Accrual velocity is the single recruitment performance metric that sponsors, CROs, and principal investigators (PIs) care about most. A sluggish accrual velocity creates constant administrative pressure, repeated audit requests, and corrective action plans that land directly on the coordinator’s desk.

The TheraNovex Advantage: TheraNovex stabilizes accrual velocity by maintaining an active pipeline of pre-matched patients. By running continuous, background EHR surveillance and direct patient-to-trial mapping, the platform supplies an ongoing cohort of qualified candidates rather than relying on inconsistent bursts of manual searching. This consistent inflow transforms recruitment from an unpredictable crisis into a manageable, linear workflow.

Measuring What Matters: A Quick Reference for Coordinators

Translating Data into Better Trial Operations

When site leaders track productivity tracking metrics accurately, the root causes of recruitment delays shift from vague excuses to clear operational challenges:

Traditional Bottleneck TheraNovex Intervention ┌─────────────────────────┐ ┌─────────────────────────┐ │ Low Screening Yield │ ────► │ High-Precision AI Match │ ├─────────────────────────┤ ├─────────────────────────┤ │ Slow First Contact │ ────► │ Automated Lead Triage │ ├─────────────────────────┤ ├─────────────────────────┤ │ High Screen Failures │ ────► │ Multi-layer Inclusion │ └─────────────────────────┘ └─────────────────────────┘

Harry Hunter

Director of Patient Recruitment Strategy

Specializing in protocol-matched patient acquisition, multi-site enrollment operations, and pre-screening workflows for clinical trials

Harry Hunter on LinkedIn